Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. - Wikidata - awgldk - TriplyDB

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.

http://www.wikidata.org/entity/Q37438148

about

HER2 targeted molecular MR imaging using a de novo designed protein contrast agent Predictive and prognostic molecular markers for cancer medicine Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.Expression of recombinant multi-coloured fluorescent antibodies in gor -/trxB- E. coli cytoplasm.Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer.Genomic testing and therapies for breast cancer in clinical practice.Capacity building for assessing new technologies: approaches to examining personalized medicine in practice Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine Comparative study between quantitative digital image analysis and fluorescence in situ hybridization of breast cancer equivocal human epidermal growth factor receptors 2 score 2(+) cases.Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy.Cost-utility analyses of drug therapies in breast cancer: a systematic review.In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging.A population approach to precision medicine Using in-vivo fluorescence imaging in personalized cancer diagnostics and therapy, an image and treat paradigm.Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.Potential biomarkers in psychiatry: focus on the cholesterol system.Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing.What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer.Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.Targeting HER2 in Nuclear Medicine for Imaging and Therapy.Noninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model

P2860

Q28477503-DD4E90D6-3D2F-4848-BD9C-CC31FD107A6D Q28743108-243FB42C-A123-4834-AC15-5839513FA3AF Q33577818-621FD9BE-A676-4A75-93F8-553A555B3E74 Q34086845-C940B4ED-2C54-4645-945B-244231024D27 Q34096222-FF7784FD-91D6-4E4F-BA76-30C7EC9FEAC5 Q34104204-0ADB3846-F4A6-4135-B646-2EAA28A869AE Q34974164-35B13E07-369F-4357-90C9-F6E889B7A286 Q35167656-7A84961E-0D38-4A80-914F-87DE180A3D71 Q35195417-90898B26-C1BF-49EE-BEF2-AB3F63733B4E Q35319902-FACDC0E7-0AF8-49EE-A51E-06E91F329279 Q35750049-B8EE58DD-05FC-4F24-BAA5-06149C2DA29B Q36105964-6F43335B-A126-43E2-A0FC-4F9F5072A8A9 Q36116276-F9938732-0824-4AC5-B081-DFDAD8FE3039 Q36357046-C63BF3E8-20E8-4785-B75A-09506E556BC1 Q36776351-FA50413F-D663-4DD9-BEE1-E628E265BFE7 Q37031461-2E863820-0A7B-4C6D-9ECE-78F06329D5E4 Q37889274-C4F24E26-95DC-4369-9F05-7175EAB51B27 Q37981261-F782A233-3746-4AAB-9663-F6E58995E2D0 Q43566770-36AEAA8A-8E84-4CA4-B7C9-F70677CBB0ED Q44983962-4A2EFDDF-30B0-4267-8B7E-6BD66DE0B5CA Q46512353-957BC681-CFF2-44C8-9AA5-F28743275A03 Q49700421-762F5924-5990-49CB-BB2D-25FA0765B568 Q58743797-D870EB94-3775-442D-BFF0-01FC16A22054

P2860

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.

http://www.wikidata.org/entity/Q37438148

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Clinical practice patterns and ...... ies in breast cancer patients.

@en

Clinical practice patterns and ...... ies in breast cancer patients.

@nl

type

label

Clinical practice patterns and ...... ies in breast cancer patients.

@en

Clinical practice patterns and ...... ies in breast cancer patients.

@nl

prefLabel

Clinical practice patterns and ...... ies in breast cancer patients.

@en

Clinical practice patterns and ...... ies in breast cancer patients.

@nl

P1433

Q37438148-232645BA-4F84-4D67-87BF-FDBBEF1E16A3

P1476

Q37438148-83745169-9916-4011-A84F-E5F144B800A9

P2093

Q37438148-0451161C-44EC-43D0-9721-E4C18DFDD228

Q37438148-0B5E1013-28D1-4491-9DCB-7EA0C7BCED6C

Q37438148-3FC6B3DD-2175-4763-BD04-A5B4C306FB23

Q37438148-717FA3AE-84B6-4E43-ABE3-BA9F159CC0C5

Q37438148-71E271F7-4E81-44CE-9161-48A2C063658C

Q37438148-F0174379-BD60-4A1C-A032-05B657F3FFDF

Q37438148-FBCACD8D-F5DC-4452-B6C1-96983991FB0C

P2860

Q37438148-084F19FC-D4BE-4EFB-B2F5-7B653C7CBF40

Q37438148-15775D81-3186-4666-8C69-C67289800F8C

Q37438148-1B426A27-F58A-4A85-9F97-63ADBB1412EF

Q37438148-3072F5A7-D7D6-418D-AF55-DAD7063DC4F8

Q37438148-33B189C5-9DC7-4C9D-BF45-0CFB695D768C

Q37438148-3879C784-3996-461E-BCE4-AEA9D849F3EC

Q37438148-4A3F7834-6476-409E-A7F0-AC6132AFCD1A

Q37438148-4AFF45B9-651B-4A45-9E66-69E6A68DBBB6

Q37438148-53E34113-0619-4792-ACAC-1E9EAFB6487E

Q37438148-7BE7ABED-8061-4BCB-84F2-D53051B2EAA9

P304

Q37438148-ADE7E546-D12C-4435-9C1A-7069FD66FE45

P31

Q37438148-11E91AFE-F36D-4EF9-A26A-01F65271C358

P356

Q37438148-60153F28-B41B-47CA-A58B-6FC9B165EC9D

P407

Q37438148-1F2792CB-CD24-474C-B8EE-ACCE41DF6D30

P433

Q37438148-B3C143A3-5FF7-4AB6-9223-89269379C49D

P478

Q37438148-5A9ED563-F48C-4E93-A53B-421BD8D2F676

P50

Q37438148-2D109E5C-04E1-4A85-AD74-89F180310318

Q37438148-80995442-E289-4FE2-B33F-6F63A299A59E

P577

Q37438148-F0D8C293-311E-433E-A646-F7B6941438CC

P5875

Q37438148-3EAF4AA5-7951-4315-9355-221A93E1FCCD

P698

Q37438148-8D127BBB-CBDE-4CB4-BD5D-CE4F9F0C3D4C

P932

Q37438148-B4652C92-549B-4FBE-BEAA-11EACC06034D

P356

P1433

P1476

Clinical practice patterns and ...... ies in breast cancer patients.

@en

P2093

Elena B Elkin

http://www.w3.org/2001/XMLSchema#string

Ilia Ferrusi

http://www.w3.org/2001/XMLSchema#string

Jane E Brock

http://www.w3.org/2001/XMLSchema#string

Kathryn A Phillips

http://www.w3.org/2001/XMLSchema#string

Michael J Hassett

http://www.w3.org/2001/XMLSchema#string

Stephanie L Van Bebber

http://www.w3.org/2001/XMLSchema#string

Su-Ying Liang

http://www.w3.org/2001/XMLSchema#string

P2860

The meaning of translational research and why it matters

Closing the evidence gap in the use of emerging testing technologies in clinical practice

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Current perspectives on HER2 testing: a review of national testing guidelines.

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

Outcomes-based access: what will it mean for biologics?

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

Realizing the promise of genomics in biomedical research.

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.

P304

5166-5174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24574

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Deborah Marshall

Jennifer S Haas

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26811570

http://www.w3.org/2001/XMLSchema#string

P698

19753618

http://www.w3.org/2001/XMLSchema#string

P932

2783254

http://www.w3.org/2001/XMLSchema#string